文献类型：期刊文献

英文题名：Extracellular Disintegration of ViralProteins as an Innovative Strategyfor Developing Broad-SpectrumAntivirals Against Coronavirus

作者：Sun, Ke[1];Ding, Zhe[2,3];Jia, Xiaoying[3,4];Cheng, Haonan[1];Li, Yingwen[2,3];Wu, Yan[4];Li, Zhuoyu[1];Huang, Xiaohua[1];Pu, Fangxu[1];Li, Entao[5];Wang, Guiyou[1];Wang, Wei[3,4];Ding, Yun[1];Wong, Gary[2];Chiu, Sandra[5,6];Lan, Jiaming[2];Hu, Aiguo[1]

机构：[1]East China Univ Sci & Technol, Shanghai Key Lab Adv Polymer Mat, Sch Mat Sci & Engn, Shanghai 200237, Peoples R China;[2]Chinese Acad Sci, CAS Key Lab Mol Virol & Immunol, Shanghai 200031, Peoples R China;[3]Univ Chinese Acad Sci, Beijing 100049, Peoples R China;[4]Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, State Key Lab Virol, Wuhan 430071, Peoples R China;[5]Univ Sci & Technol China, Div Life Sci & Med, Hefei 230027, Anhui, Peoples R China;[6]Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, Dept Clin Lab, Hefei 230001, Anhui, Peoples R China

年份：2024

卷号：6

期号：2

起止页码：487

外文期刊名：CCS CHEMISTRY

收录：WOS:【ESCI(收录号:WOS:001162205000019)】；

语种：英文

外文关键词：enediyne; broad spectrum antiviral; pro-tein disintegration; coronavirus; polyanions

摘要：Thecoronavirusdisease2019(COVID-19)pandemic,caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed millions of livesand caused innumerable economic losses world-wide. Unfortunately, state-of-the-art treatments stilllag behind the continual emergence of new variants.Key to resolving this issue is developing antivirals todeactivate coronaviruses regardless of their structural evolution. Here, we report an innovative antiviral strategy involving extracellular disintegration ofviral proteins with hyperanion-grafted enediyne(EDY) molecules. The core EDY generates reactiveradical species and causes significant damage to thespike protein of coronavirus, while the hyperaniongroups ensure negligible cytotoxicity of the molecules. The EDYs exhibit antiviral activity down tonanomolar concentrations, and the selectivity indexof up to 20,000 against four kinds of human Mcoronavirus, including the SARS-CoV-2 Omicronvariant, suggesting the high potential of this newstrategy in combating the COVID-19 pandemic and afuture"disease X."